Clinical application of imaging omics to predict IDH mutation and 1P / 19Q deletion in glioma diagnosis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046868

Enrollment

Unknown

Registered

2021-05-29

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Group Glioma:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. For intracranial space-occupying lesions, multimodal magnetic resonance examination was completed before surgery, and there were cases of glioma confirmed by pathology after surgery, and the patient's consent was solicited; 2. Pathological data: Pathological images and characteristics were recorded, including key molecular marker information (1P /19q, IDH mutation results after surgery), and a full-court digital section with a 40X scan was also provided.

Exclusion criteria

Exclusion criteria: 1. Implantation of pacemaker and claustrophobic syndrome can not cooperate with examination; 2. The image quality of MRI examination is poor; 3. Previous history of head surgery and massive cerebral infarction; 4. Previous history of genetic diseases.

Design outcomes

Primary

Measure	Time frame
Skull 3.0T high resolution magnetic resonance;	—

Countries

China

Contacts

Public ContactDai Yueli

The Second Affiliated Hospital of Nanhua University

neihanzidyl@163.com+86 15973428652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026